Home
About
Services
Partners
Client Portfolio
News
Contact
JD.com beats forecasts with 22 percent revenue rise
February 28, 2019
Air Canada raises long-term profit margin goals
February 28, 2019
0
Novartis faces shareholder criticism over drug prices at AGM
Published by
Muller&Green
at
February 28, 2019
Categories
RSS
Tags
Novartis’s shift into high-tech drugs won praise for providing patients with new options but criticism over prices that may run into the millions of dollars at the Swiss drugmaker’s annual general meeting on Thursday.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more